People sense that a part of their body is hurting when nerves from the affected area send signals to the brain through what is called the pain pathway.
"A compound that blocks Nav1.7 channels is of particular interest for us," said research team leader Professor Glenn King from The University of Queensland's Institute for Molecular Bioscience, Australia.
"Previous research shows indifference to pain among people who lack Nav1.7 channels due to a naturally-occurring genetic mutation - so blocking these channels has the potential of turning off pain in people with normal pain pathways," King said.
"A conservative estimate indicates that there are nine million spider-venom peptides, and only 0.01 per cent of this vast pharmacological landscape has been explored so far," said researcher Dr Julie Kaae Klint.
The challenge was to build a research method that could search through this huge number of peptides, looking for the ones that could be useful.
The research team built a system that could rapidly analyse the compounds in spider venoms. Using their novel approach, venoms from 206 species of spider were screened, revealing that 40 per cent of the venoms contained at least one compound that blocked human Nav1.7 channels.
Together these properties make it particularly exciting as a potential painkiller, researchers said.
"Untapping this natural source of new medicines brings a distinct hope of accelerating the development of a new class of painkillers that can help people who suffer from chronic pain that cannot be treated with current treatment options," said Klint.
The research is published in the British Journal of Pharmacology.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
